


EVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm sign strategic supply agreement

30 June 2025 | News

Strengthen Cross-Border Collaboration for a More Resilient and Accessible Healthcare Supply Chain



EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and Zhejiang Jinhua CONBA, one of China's most prominent pharmaceutical groups, have entered into a strategic supply agreement, marking a significant step forward in global healthcare collaboration.

The agreement, signed during CPHI China 2025, represents a high-level partnership between two influential players in their respective regions. It aims to support a more sustainable, agile, and secure pharmaceutical supply chain, ultimately contributing to greater accessibility for patients across emerging markets.

The collaboration reflects a shared commitment to long-term supply reliability, technical excellence, and patient-centric delivery models.

“We are reinforcing our commitment to innovation with access for patients across the Middle East & Africa,” said Riad Armanious, CEO of EVA Pharma. “This partnership with Zhejiang Jinhua CONBA sets a new benchmark for trust-based, cross-border supply collaborations, at a time of rising global demand for supply chain resilience. With decades of experience, EVA Pharma has built one of the region’s most agile pharmaceutical platforms and by deepening our foothold in China, we are expanding our ability to deliver timely, affordable, and high-quality treatments across borders.”

“As a key player in China’s pharmaceutical industry, CONBA Bio-Pharm is committed to advancing high-quality, reliable manufacturing that serves both domestic and international health needs,” said Bin Yu, President of Zhejiang Jinhua CONBA Bio-Pharm. “This strategic partnership with EVA Pharma reflects our shared commitment to building a more resilient and accessible global healthcare supply chain. By combining our strength with EVA Pharma’s regional reach and patient-focused mission, we look forward to delivering sustainable impact across key markets.”